Internationale Zeitschrift für Entzündung, Krebs und integrative Therapie

Abstrakt

The Application and Progress of Immune Checkpoint Inhibitors in the Immunotherapy of Non-Small Cell Lung Cancer

Dou Peng Hui*, Hounsinou Giscard Kevin Joanes, Zun Xian Wang, Linrui Li and Meiqi Lu

For several years now, the therapeutic situation in the management of non-small cell lung cancer using the immunotherapy protocol has allowed the approval of several drugs. These different drugs have shown fantastic results but with the downside of some side effects whether in monotherapy or in dual therapy with chemotherapy or radiotherapy.

The aim of our work was to review the different drugs administered in first- or second-line therapy for non-smallcell lung cancer and other drugs that are still in clinical research or have been dropped. In view of all this, the vaccine is being considered, but its application is still very much in doubt in the scientific community.